ReviewOncology letters2026
Targeting ICMT: A promising strategy in cancer treatment (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein prenylation is a prevalent post-translational modification of proteins, pivotal in regulating their biological functions. It influences critical cellular processes such as signal transduction, cell cycle control and apoptosis. Isoprenylcysteine carboxymethyltransferase (ICMT) serves as the terminal enzyme in this pathway, catalyzing the methylation of proteins containing-CAAX or -CXC motifs, thereby modulating their subcellular localization and biological activity. Accumulating evidence indicates that ICMT inhibition disrupts key malignant phenotypes, such as tumor cell proliferation, migration and invasion, and attenuates the functional dependency of RAS proteins on prenylation. Consequently, ICMT has emerged as an important regulator of cancer-associated signaling and a potential therapeutic target. This review summarizes current knowledge on ICMT-mediated protein modification, its regulatory mechanisms and its roles in cancer progression, with the aim of highlighting recent advances and discussing the therapeutic implications of targeting ICMT in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.